Skip to Main Content
Phase III

BETA-Text: Evaluating the Efficacy of a Novel, Interactive, Bidirectional Text-messaging Application to Increase Persistence to Adjuvant Endocrine Therapy for Stage I-III Hormone Receptor Positive Breast Cancer

  • Study HIC#:2000024495
  • Last Updated:07/15/2021

Brief Summary:

  1. The primary objective is to compare rates of persistence (continuation) of any endocrine therapy (ET) between patients assigned to standard of care follow-up (control arm) versus standard of care plus a bi-directional text messaging intervention (intervention arm)
  2. The secondary objectives are:

    (i) To assess time to permanent discontinuation of ET (switching from an aromatase inhibitor to another ET is permitted). The investigators will also account for treatment breaks.

    (ii) To assess QOL at baseline, and at 6 and 12 months after initiation of ET (FACT-ES1, Brief Pain Inventory2, Overall Treatment Burden3,4, individual symptom LASA scales4) and compare between arms (iii) To assess adherence self-efficacy (SEAMS5 tool, Voils Extent of Non-Adherence Scale6), financial burden (COST tool7,8), beliefs about medications (modified BMQ tool9,10), and perceived ability to communicate with one's physician (PEPPI11 tool) and compare between arms (iv) To compare the time to endocrine therapy discontinuation in both the intervention and control arms (v) To characterize factors (including clinicopathologic features, socioeconomic status, and comorbidities) associated with non-adherence in both the intervention arm and the control arm, which may enable us to identify women who are at particularly high risk of non-adherence.

    (vi) To assess adherence to medication as reported through the BETA-Text intervention (vii) To collect the time to onset and trend of severity of side effects in women assigned to the text messaging intervention.

  • Start Date07/22/2019
  • End Date12/31/2021

Trial Purpose and Description

Primary Outcome Measures  :

  1. Persistence to endocrine therapy at one year [ Time Frame: 1 year ]

Secondary Outcome Measures  :

  1. Time to discontinuation of endocrine therapy [ Time Frame: 1 year ]
  2. Patient-reported Quality of life [ Time Frame: 1 year ]FACT-ES (45 items). The survey assesses items on a 0-4 scale, where 0 is lack of a symptom and 4 is high degree of a symptom. There are 5 domains: physical well-being (7 items), social/family well-being (7 items), emotional well-being (6 items), functional well-being (7 items), and additional concerns/symptoms (14 items).
  3. Pain (worst, least, current, average, and interference of pain) [ Time Frame: 1 year ]Brief Pain Inventory (15 items), which measures worst pain, average pain, least pain, current pain, and pain interference on a 0-10 scale, where higher numbers indicate higher levels of pain.
  4. Treatment Burden [ Time Frame: 1 year ]Overall Treatment Burden (1 item), which assess the overall burden of treatment on a 0-100 visual analog scale. Higher numbers are indicative of higher treatment burden.
  5. Self-Reported Adherence [ Time Frame: 1 year ]Voils Extent of Non-Adherence Tool (3 items); items are scored 1-5; however, responses are dichotomized into either "adherent" (1) or "non-adherent" (2-5). A respondent must answer "1" for all three questions in order to be classified as "adherent"
  6. Reasons for Non-Adherence [ Time Frame: 1 year ]Voils Reasons for Non-Adherence Tool (24 items). Each item is measured on a scale of 1-5, with higher scores indicating more agreement with the particular item.
  7. Adherence self-efficacy [ Time Frame: 1 year ]SEAMS Questionnaire (13 items); items are scored 1-3 (range 13-39); the higher the score, the higher the self-efficacy of taking medication
  8. Financial burden [ Time Frame: 1 year ]COST tool (11 items); items are scored 0-4, some items are reverse scored; the lower the score, the worse the financial toxicity.
  9. Beliefs about medication [ Time Frame: 1 year ]BMQ tool (18 items); assessing patients' beliefs about the necessity of prescribed medication for controlling their illness and their concerns about the potential adverse consequences of taking it; higher scores indicate stronger beliefs in the concepts represented by the scale. There are an additional 8 questions which similarly address Overuse and Harm.
  10. Communication with one's physician [ Time Frame: 1 year ]PEPPI instrument (5 items); range of scores 5-25, where high scores indicate patient-reported better patient-physician communication and interaction
  11. Time to onset and trend of severity of side effects [ Time Frame: 1 year ]

Eligibility Criteria

Inclusion Criteria:

  1. Patients with histologically confirmed stage I-III, estrogen and/or progesterone receptor positive, as defined by ASCO-CAP guidelines, invasive breast cancer for whom adjuvant hormonal therapy is indicated following standard NCCN practice guidelines.42
  2. Patients must initiate an aromatase inhibitor (AI), with the choice of AI (letrozole, anastrozole, or exemestane) left to the discretion of the treating provider (have just started or plan to start within 4 weeks)
  3. Patients with synchronous bilateral breast cancers are eligible if both tumors are hormone receptor positive.
  4. Patient must be able to provide informed consent and agree to:
    1. Complete questionnaires according to the pre-specified study design
    2. Own or have access to a personal cell phone, agree to send and receive text messages (including any costs), and share their personal cell phone number to receive text messages.
    3. Be able to read/speak English
    4. To allow research staff to contact their pharmacies to determine prescription refill dates.

Exclusion Criteria:

  1. Patients with history of prior stage I-III breast cancer in the same or contralateral breast are not eligible (because exposure to prior endocrine therapy may confound results)
  2. Patients with metastatic breast cancer.
  3. Patients with ductal carcinoma in situ (DCIS) or other pre-malignant lesions of the breast receiving endocrine therapy as chemoprevention.
  4. Prior treatment with an aromatase inhibitor, regardless of indication.
  5. Prior tamoxifen for the current cancer (prior tamoxifen for DCIS or a different cancer is permitted).


For more information about this study, contact: